Skip to content

This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Learn more

.

Latest News

Actineer Achieves Sustainable Radium-226 Recycling

Chalk River, Ontario, July 14, 2026

Milestone Lays Foundation for Scalable Supply Chain Designed to Meet Growing Demand of Promising Medical Radioisotope in Oncology

Actineer, a joint venture between Canadian Nuclear Laboratories (CNL) and ITM Isotope Technologies Munich SE (ITM), today announced the successful completion of a closed-loop process to recycle Radium‑226 (Ra-226), the essential precursor material of Actinium-225 (Ac-225), a rare medical radioisotope that is highly sought-after for its role in the development of targeted alpha therapy (TAT) in oncology.

Read More
.

More News

July 13th, 2026

Actineer Achieves Sustainable Radium-226 Recycling

Actineer, a joint venture between Canadian Nuclear Laboratories (CNL) and ITM Isotope Technologies Munich SE (ITM), today announced...

Learn more
January 26th, 2026

Actineer is strengthening the Operational Model

Actineer marks two years of progress, securing key agreements between ITM and CNL to strengthen operations and expand Actinium 225...

Learn more
May 15th, 2025

CNL awarded for production of Ac-225 for Actineer

Canadian Nuclear Isotope Council honours CNL, Sylvia Fedoruk Centre and Advanced Cyclotron Systems for first cyclotron irradiation of...

Learn more
January 16th, 2025

Actineer Appoints New President and CEO

Actineer, a joint venture between ITM and Canadian Nuclear Laboratories (CNL) Ltd., today announced the appointment of Joseph...

Learn more
October 17th, 2024

Actineer Advances
Ac-225 Production

Chalk River, Ontario, October 17, 2024 – Actineer, the joint venture between ITM and Canadian Nuclear Laboratories (CNL) Ltd., has...

Learn more
December 7th, 2023

Actinium-225 production

Toronto – December 7 2023 – In support of Canadian Nuclear Isotope Council’s (CNIC) goal of ensuring a reliable supply of medical...

Learn more
October 18th, 2023

ITM and CNL Announce the Launch of Actineer

ITM Isotope Technologies Munich SE (ITM), a leading radio- pharmaceutical biotech company, and Canadian Nuclear Laboratories (CNL)

Learn more

Actineer is strengthening the Operational Model

Actineer Celebrates Two Years with Key Agreements to Advance Strategic Growth

Chalk River, Ontario, January 26, 2026

Two Years of Progress

This year marks the third anniversary of Actineer, the joint venture between ITM Isotope Technologies Munich SE (ITM) and Canadian Nuclear Laboratories (CNL). Over the past two years, the partnership has taken meaningful steps to establish an efficient operating model based on its corporate structure and long-term strategy, positioning the joint venture to support the growing global demand for Actinium-225 (Ac-225).

Read more

January 26, 2026

.

Actineer Quotes

.

Our joint venture Actineer has been launched with the overall goal to ensure access to Ac-225 as a next generation radioisotope through an innovative technology.
With the foundation of Actineer we have committed us to establish a reliable, long term and substantial production of Ac-225 in high quality standards.
This Canada based company will facilitate ground breaking research activities leading to novel cancer treatments urgently needed by many patients worldwide.
Dr. Andreas Benischke,
VP Global Actinium Lead of ITM
.

It is our role to drive nuclear innovation in Canada, to bring private and public expertise together to spark these new initiatives that will ultimately benefit the health of Canadians and bring new jobs to Canada. We are building on decades of Canada’s world-leading isotope innovation, and have found the key to success is collaboration, partnership, and strong leadership. We are pleased to support the joint venture between CNL and ITM with shared values to bring this potentially lifesaving therapy to the world.
Fred Dermarkar,
President and CEO of AECL
.

Actineer is poised to become one of the major global suppliers of Actinium-225. I am privileged to work with such premier institutions as CNL and ITM and am eager to leverage my expertise and work together with the Actineer team to achieve this goal and thereby support the development of innovative targeted alpha radiopharmaceuticals for the treatment of challenging cancer indications.
Joseph Oliverio,
President and CEO
.

Targeted alpha therapies based on Actinium-225 are gaining increasing importance in addition to the well-established beta emitters such as our highly-pure non-carrier-added (n.c.a.) Lutetium-177. Joining forces with CNL provides us the opportunity to extend our therapeutic portfolio as we continue striving to meet the needs of healthcare professionals and cancer patients worldwide.
Steffen Schuster,
Vice Chairman of the Board of ITM
.

Actineer, the joint venture between ITM and CNL, is addressing the growing and urgent global demand for Actinium-225—a rare medical radioisotope that enables the development of innovative therapies for hard-to-treat tumors. By ensuring a stable, scalable supply of this critical resource, Actineer helps to advance both clinical trials and the development of potential life-saving treatments for cancer patients worldwide.
Dr. Andrew Cavey,
CEO of ITM

Actineer, a Joint Venture between ITM and CNL, appoints new President and CEO

Actineer Appoints Radiopharmaceutical Executive Joseph Oliverio as President and CEO

Chalk River, Ontario, January 16, 2025 – Actineer, a joint venture between ITM and Canadian Nuclear Laboratories (CNL) Ltd., today announced the appointment of Joseph Oliverio as President and Chief Executive Officer. With extensive industry leadership experience, Mr. Oliverio is poised to drive Actineer’s global expansion in Actinium-225 (Ac-225) production. 

Read more

January 16, 2025

.

Actineer, a Joint Venture between ITM and CNL, Advances Actinium-225 Production

Successful Cyclotron Irradiation of Ra-226 Sets the Stage for Actineer's Large-Scale Ac-225 Production for Cancer Therapies

Chalk River, Ontario, October 17, 2024 – Actineer, the joint venture between ITM and Canadian Nuclear Laboratories (CNL) Ltd., has successfully produced Actinium-225 (Ac-225) by irradiating Radium-226 (Ra-226) in a cyclotron. This production milestone achievement will enable the joint venture to provide GMP-grade Ac-225 to customers by mid-2025, alongside the submission of a US Drug Master File (DMF). 

Read more

October 17, 2024

.
mile